Article and Video CATEGORIES
As part of the series co-sponsored by GRACE and LUNGevity, challenging cases in lung cancer discussed with multiple experts, here's one on the common but vexing scenario of a patient with mediastinal node-positive (stage IIIA N2) NSCLC. This is among the most controversial clinical settings in lung cancer, as illustrated by the wide range of answers of how the experts in this program would manage the same patient. Some of the experts even note that the way that such a patient would be managed at their center would depend on the people weighing in on the case. This also underscores how important a multidisciplinary approach, often developed in a "tumor board" conference, is for developing treatment plans, ideally by a consensus among the various medical specialists involved.
Here's the audio podcast, video podcast, and transcript for the program (really not much video to follow for this one).
[powerpress]
grace-cases-stage-iiia-n2-nsclc-of-questionable-resectability-audio-podcast
grace-cases-stage-iiia-n2-nsclc-of-questionable-resectability-transcript
We'd love to hear your comments and questions.
There are still several more interesting cases in this series, but we'll take a break from them for a while to bring you the podcasts for the ASCO Lung Cancer Highlights webinar from a couple of weeks ago. Look for those over the next couple of weeks.
And thanks again to LUNGevity Foundation for their support in developing the case series, the ASCO highlights program, and the podcasts for all of these activities!
Please feel free to offer comments and raise questions in our
discussion forums.
Forum Discussions
Hi elysianfields and welcome to Grace. I'm sorry to hear about your father's progression.
Unfortunately, lepto remains a difficult area to treat. Recently FDA approved the combo Lazertinib and Amivantamab...
Hello Janine, thank you for your reply.
Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...
Hi elysianfields,
That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...
Recent Comments
That's…